{"schema_version":"secwatch.filing_event.v1","accession":"0001326110-26-000071","form_type":"8-K","ticker":"IBRX","cik":"0001326110","company_name":"ImmunityBio, Inc.","filed_at":"2026-07-30T21:19:45+00:00","discovered_at":"2026-07-30T21:22:00.474483+00:00","generated_at":"2026-07-30T21:22:10.839123+00:00","sec_items":["7.01","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"ImmunityBio gets UAE marketing authorization for ANKTIVA in bladder and lung cancers","bullets":["UAE approved ANKTIVA for BCG-unresponsive NMIBC (CIS and papillary) and metastatic NSCLC after checkpoint failure.","NMIBC CIS cohort (N=100): 71% complete response rate; median DoR 26.6 months, with responses beyond 54 months.","Papillary-only cohort (N=80): 12-month disease-free survival 58.2%; 83.1% cystectomy-free at 36 months.","NSCLC checkpoint-refractory (N=79): median OS 14.6 months; 16.2 months in patients with ALC ≥1,000.","Authorization expands ANKTIVA's global regulatory footprint to 34 countries; validity through July 2031."],"urls":{"canonical":"https://secwatch.observer/filing/0001326110-26-000071","json":"https://secwatch.observer/filing/0001326110-26-000071.json","markdown":"https://secwatch.observer/filing/0001326110-26-000071.md","text":"https://secwatch.observer/filing/0001326110-26-000071.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1326110/000132611026000071/0001326110-26-000071-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1326110/000132611026000071/ibrx-20260729.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-07-30T21:22:10.839123+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}